贝特类药物在血脂治疗中的作用课件.ppt

上传人（卖家）：晟晟文业

文档编号：3815951

上传时间：2022-10-15

格式：PPT

页数：18

大小：138.05KB

文档加载中……请稍候！
如果长时间未打开，您也可以点击刷新试试。

下载文档到电脑，查找使用更方便

19 文币

交易提醒：下载本文档，相应价格的文币将全额进入上传人（卖家）的账号。立即下载优惠套餐（点此详情）

【下载声明】
1. 本站全部试题类文档，若标题没写含答案，则无答案；标题注明含答案的文档，主观题也可能无答案。请谨慎下单，一旦售出，不予退换。
2. 本站全部PPT文档均不含视频和音频，PPT中出现的音频或视频标识（或文字）仅表示流程，实际无音频或视频文件。请谨慎下单，一旦售出，不予退换。
3. 本页资料《贝特类药物在血脂治疗中的作用课件.ppt》由用户（晟晟文业）主动上传，其收益全归该用户。163文库仅提供信息存储空间，仅对该用户上传内容的表现方式做保护处理，对上传内容本身不做任何修改或编辑。若此文所含内容侵犯了您的版权或隐私，请立即通知163文库（点击联系客服），我们立即给予删除！
4. 请根据预览情况，自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
5. 本站所有资源如无特殊说明，都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器，压缩文件请下载最新的WinRAR软件解压。

配套讲稿：: 如PPT文件的首页显示word图标，表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
特殊限制：: 部分文档作品中含有的国旗、国徽等图片，仅作为作品整体效果示例展示，禁止商用。设计者仅对作品中独创性部分享有著作权。
关键词：: 类药物血脂治疗中的作用课件

资源描述：: 1、COOCCH3COOCHCH3CH3ClCH3OCCH3COOC2H5CH3ClCH3CH3OCH2CH2CH2CH2CH3COOHCH3CFenofibrateClofibrateGemfibrozil%ReductionHMG CoA RI20-50%Bile acid resins15-25%Dose dependentNicotinic acid15-30%Gemfibrozil10-15%Fixed doseFenofibrate10-25%HDL-CTriglycerideNicotinic acid10-25%20-50%Fibrates 10-25%20-50%HMG CoA
2、RI 5-10%10-25%Bile acid resins3-5%0-20%Indications:Adjunctive therapy to dietHypertriglyceridemia(Type IV and V)Combined hyperlipidemia(Type IIb)with low HDL who do not respond to NAMechanism of Action:Increases peripheral lipolysis and decreases hepatic TG productionEfficacy:Decreases TG 25-50%LDL
3、decreases,remains the same or increasesIncreases HDL 15-25%in hypertriglyceridemiaSide Effects:GI upset(8%),cholelithiasis,myositis,abn LFTsContraindications:Hepatic or renal dysfunctionPre-existing gallbladder diseaseIntervention Trials:Helsinki Heart Study,LOCAT,BECAIT,VA-HIT,BIPGoldberg AC,et al.
4、Clin Ther.1989;11:69-83.*These are mean percentage changes,not percentage changes in means.NS=Not statistically significant when compared to placebo(12%increase).FenofibrateGroup A(350-499 mg/dL)Before(mean SE)After(mean SE)PercentChange*PTotal cholesterol251.8 5.3227.4 6.7-9.10.001VLDL-cholesterol9
5、2.1 6.845.8 4.5-44.70.001LDL-cholesterol128.4 7.1136.7 5.3NS0.8570HDL-cholesterol33.7 1.140.3 1.9+19.60.0014Total triglyceride432.0 19.1223.4 13.9-46.20.001VLDL-triglyceride349.8 34.3177.8 24.6-44.10.001Goldberg AC,et al.Clin Ther.1989;11:69-83.*These are mean percentage changes,not percentage chang
6、es in means.FenofibrateGroup B(500-1500 mg/dL)Before(mean SE)After(mean SE)Percent Changes*PTotal cholesterol261.0 6.7223.3 6.6-13.80.0001VLDL-cholesterol126.2 7.053.7 3.4-49.40.0001LDL-cholesterol103.1 6.8131.0 6.0+45.00.0002HDL-cholesterol29.6 1.336.0 1.8+22.90.0029Total triglyceride725.6 37.4308.
7、0 19.9-54.50.0001VLDL-triglyceride543.3 50.8204.7 23.0-50.60.0001Goldberg AC,et al.Clin Ther.1989;11:69-83.nMany patients with markedly elevated triglycerides have reduced LDL-C levels because of a derangement in the normal composition of LDL.nThis derangement produces a triglyceride-rich and choles
8、terol-depleted LDL.nWhen triglycerides are reduced with therapy,the composition of LDL normalizes.This can elevate LDL-C levels.Brown WV,et al.Arteriosclerosis.1986;6:670-678.p0.10Percentage Changes at Endpoint from Baseline Values after 24 Weeks of Double Blind Study vs.Placebo(Plb)Type IIa (%)Type
9、 IIb (%)Fenon=92Plbn=88Fenon=24Plb n=22Total Cholesterol-17.5-0.4-15.8+4.6LDL Cholesterol-20.3+0.4-6.1-0.5HDL Cholesterol+11.1-1.2+15.3-3.5Total Triglycerides-37.9-4.2-44.6+22.3LDL/HDL Cholesterol-27.1-1.9-13.3 0.0VLDL Cholesterol-38.4-2.5-52.7+8.4(Randomized,Crossover Study)Farnier M,et al.Arch Int
10、 Med.1994;154:441-449.Fenofibrate200 mg/daySimvastatin20 mg/daySimvastatin20 mg/dayFenofibrate200 mg/dayType IIa,n=16Type IIb,n=14Type IIa,n=16Type IIb,n=14Group 1Group 2IIII I I I03 6 Months-28-28-34-36-37-50-40-30-20-100Total-CLDL-CHDL-CTrigFenofibrateSimvastatinFarnier M,et al.Arch Int Med.1994;1
11、54:441-449.(Type IIa)%Change from BaselineNCNC=no changeNCNC-23-21-25-302917-5218-60-45-30-150153045Total-CLDL-CHDL-CTrigFenofibrateSimvastatinFarnier M,et al.Arch Int Med.1994;154:441-449.(Type IIb)%Change from BaselinenLipoprotein and Coronary Atherosclerosis Study(LCAS)nPost Coronary Artery Bypas
12、s Graft Trial(Post-CABG)nBezafibrate Coronary Atherosclerosis Intervention Trial(BECAIT)nLopid Coronary Angiography Trial(LOCAT)Hypothesis:Gemfibrozil treatment of“isolated”low HDL-C will 2 CHD events.Subjects:n2531 male veterans 74 year(avg 64)n2 prevention(MI,revasc,angina,+angio)nHDL 40,LDL 140,T
13、G 300 mg/dLTreatment:gemfibrozil 600 mg bidEndpoints:nonfatal MI,CHD deathFollow-up:5.1 yearsRubins HB et al.N Engl J Med 1999;341:410-418.Habits/MedsCigarettes21%DM(Hx)25%ASA82%blocker43%ACEI21%DemographicsBMI 29+5WHR 0.96+0.05LipidsHDL-C 32 mg/dlLDL-C 111 mg/dlTG 161 mg/dlRubins HB et al.N Engl J
14、Med 1999;341:410-418.Rubins HB et al.N Engl J Med 1999;341:410-418.ParameterPlacRx%PHDL-C 32 34 6%.001LDL-C113113 0%NSTG16611531%.001NFMI/CHD275219 22%.006Stroke(confirmed)76 58 25%.11+stroke330258 24%2.0)-Concomitant medications:Itraconazole,Ketoconazole Cyclosporin AErythromycin-Age 70 years演讲完毕，谢谢观看！Thank you for reading!In order to facilitate learning and use,the content of this document can be modified,adjusted and printed at will after downloading.Welcome to download!汇报人：XXX 汇报日期：20XX年10月10日

展开阅读全文

163文库所有资源均是用户自行上传分享，仅供网友学习交流，未经上传用户书面授权，请勿作他用。

关于本文

本文标题：贝特类药物在血脂治疗中的作用课件.ppt
链接地址：https://www.163wenku.com/p-3815951.html

晟晟文业

内容提供者

实名认证

联系作者